Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XW001 inhalation in children with RSV infection
NCT05779995Phase 2Completed
- Sponsor
- Sciwind Biosciences
- Start
- Apr 2023
- Primary completion
- Oct 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of xw001 in respiratory syncytial virus infection (RSV) (6 arms), sponsored by Sciwind Biosciences. Primary endpoint: Incidence of Adverse Events. Started Apr 2023; status: completed.
02
Drugs
xw001
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05779995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05779995.